Open AccessA network meta-analysis for safety of endothelin receptor antagonists in pulmonary arterial hypertension
Author(s) -
Yijing Zhang,
Na Wang,
Gu Z,
Anhua Wei,
An-Ni Cheng,
Shasha Fang,
Hongli Du,
Linzhao Wang,
Guoqing Zhang
Publication year - 2019
Publication title -
cardiovascular diagnosis and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.83
H-Index - 22
eISSN - 2223-3660
pISSN - 2223-3652
DOI - 10.21037/cdt.2019.03.02
Subject(s) - ambrisentan , bosentan , medicine , peripheral edema , endothelin receptor , liver function , placebo , meta analysis , cardiology , gastroenterology , adverse effect , pathology , receptor , alternative medicine
Currently, direct comparative safety between endothelin receptor antagonists (ERAs) in pulmonary arterial hypertension (PAH) is limited. Thus, a systematic review with network analysis was conducted.